Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 9,669 shares of the business's stock in a transaction on Tuesday, December 27th. The shares were sold at an average price of $15.02, for a total transaction of $145,228.38. Following the sale, the chief executive officer now directly owns 173,166 shares of the company's stock, valued at approximately $2,600,953.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Dipal Doshi also recently made the following trade(s):

• On Thursday, December 29th, Dipal Doshi sold 400 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.01, for a total transaction of $6,004.00.
• On Monday, November 28th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.91, for a total transaction of $27,820.00.
• On Thursday, October 27th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $21.66, for a total transaction of $43,320.00.
• On Monday, October 24th, Dipal Doshi sold 2,342 shares of Entrada Therapeutics stock. The stock was sold at an average price of $19.30, for a total transaction of $45,200.60.
• On Thursday, October 20th, Dipal Doshi sold 811 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.01, for a total transaction of $14,606.11.

Entrada Therapeutics Stock Down 4.2 %

TRDA opened at $13.52 on Friday. The firm has a 50-day simple moving average of $18.00 and a two-hundred day simple moving average of $14.61. Entrada Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $24.38. The company has a market capitalization of $424.61 million, a PE ratio of -4.33 and a beta of -0.95.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. William Blair reaffirmed an "outperform" rating on shares of Entrada Therapeutics in a report on Friday, October 14th. The Goldman Sachs Group upped their target price on shares of Entrada Therapeutics from $13.00 to $18.00 and gave the stock a "neutral" rating in a report on Tuesday, November 8th.

Institutional Trading of Entrada Therapeutics

Several hedge funds have recently made changes to their positions in the business. Fred Alger Management LLC purchased a new stake in shares of Entrada Therapeutics during the 3rd quarter valued at about $283,000. State Street Corp raised its position in Entrada Therapeutics by 10.3% in the 3rd quarter. State Street Corp now owns 33,294 shares of the company's stock worth $525,000 after purchasing an additional 3,100 shares during the period. Vanguard Group Inc. raised its position in Entrada Therapeutics by 14.1% in the 3rd quarter. Vanguard Group Inc. now owns 870,147 shares of the company's stock worth $13,714,000 after purchasing an additional 107,783 shares during the period. Price T Rowe Associates Inc. MD raised its position in Entrada Therapeutics by 21.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,972,050 shares of the company's stock worth $46,840,000 after purchasing an additional 534,552 shares during the period. Finally, Laurion Capital Management LP raised its position in Entrada Therapeutics by 54.2% in the 3rd quarter. Laurion Capital Management LP now owns 199,066 shares of the company's stock worth $3,137,000 after purchasing an additional 70,000 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

About Entrada Therapeutics

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

Further Reading

• Get a free copy of the StockNews.com research report on Entrada Therapeutics (TRDA)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.